GLP1 weight loss injections may reduce asthma symptoms
Emerging research suggests that GLP-1 receptor agonists (such as semaglutide and liraglutide), widely used for type 2 diabetes and obesity, may also have benefits for asthma control. Here’s how they might help:
Potential Mechanisms Linking GLP-1 Drugs to Asthma Improvement
- Anti-Inflammatory Effects
- GLP-1 drugs reduce systemic inflammation, which plays a key role in asthma.
- They may lower pro-inflammatory cytokines (like IL-6, TNF-α) linked to airway inflammation.
- Weight Loss & Reduced Mechanical Stress on Lungs
- Obesity worsens asthma by increasing pressure on the lungs and promoting inflammation.
- GLP-1-induced weight loss can improve lung function and reduce asthma severity.
- Direct Effects on Airway Smooth Muscle
- Some preclinical studies suggest GLP-1 receptors in the lungs may help relax airway smooth muscle, reducing bronchoconstriction.
- Improved Insulin Resistance & Metabolic Effects
- Insulin resistance is linked to worse asthma outcomes; GLP-1 drugs improve metabolic health, which may indirectly benefit asthma.
Evidence So Far
- Observational Studies: Some real-world data show that diabetic patients on GLP-1 drugs have fewer asthma exacerbations.
- Animal Studies: GLP-1 agonists reduced airway inflammation in mice with allergic asthma.
- Clinical Trials Needed: No large human trials have confirmed this yet, but studies are underway.
While not yet FDA-approved for asthma, GLP-1 drugs may offer dual benefits for people with obesity-related asthma or metabolic dysfunction. If future trials confirm these effects, they could become a novel adjunct therapy for asthma management.
Reference:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9727043
https://www.abdn.ac.uk/news/24561
https://www.sciencedirect.com/science/article/abs/pii/S0954611125002598
Medications that have been suggested by doctors worldwide are available on below link
https://mygenericpharmacy.com/category/disease/asthma-allergies